The Bulletin
The Times


.

Mabwell Receives NMPA Approval for Albipagrastim alfa for Injection (MAILISHENG)

  • Written by PR Newswire

SHANGHAI, May 30, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that Albipagrastim alfa for Injection (trade name: MAILISHENG, R&D code: 8MW0511) developed by its wholly-owned subsidiary T-mab has officially obtained the marketing approval by National Medical...

hacklink esim balkanSahabetuk casinos not on gamstopGamStopgrandpashabet girisjojobetviagra 100 mg fiyat